Skip to content
2000
Volume 20, Issue 4
  • ISSN: 1568-0266
  • E-ISSN: 1873-4294

Abstract

The development of new therapeutics is critically dependent on an understanding of the molecular pathways, the disruption of which results in neurological symptoms. Genetic and biomarker studies have highlighted immune signalling as a pathway that is impaired in patients with neurodevelopmental disorders (NDDs), and several studies on animal models of aberrant neurodevelopment have implicated microglia, the brain’s immune cells, in the pathology of these diseases. Despite the increasing awareness of the role of immune responses and inflammation in the pathophysiology of NDDs, the testing of new drugs rarely considers their effects in microglia. In this brief review, we present evidence of how the study of microglia can be critical for understanding the mechanisms of action of candidate drugs for NDDs and for increasing their therapeutic effect.

Loading

Article metrics loading...

/content/journals/ctmc/10.2174/1568026620666200221172619
2020-02-01
2025-10-20
Loading full text...

Full text loading...

/content/journals/ctmc/10.2174/1568026620666200221172619
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test